George Church joins Nuclera’s Scientific Advisory Board

31 / 10 / 2017

We are excited to announce the appointment of George Church, Professor of Harvard and MIT to the Nuclera Scientific Advisory Board.

“Demand for custom DNA is growing exponentially – with applications in manufacturing, medicine and even information storage”, said George Church. “Nuclera represents fresh approaches, which will improve cost and quality very significantly.”

“George’s experience in helping build successful biotech companies, and his visions on the future of synthetic biology will be invaluable for a young and growing company like Nuclera”, said Jiahao Huang, co-founder of Nuclera. “We are privileged to have him be the founding member of our Scientific Advisory Board, and looking forward to working with George to explore novel applications for our enzyme-based DNA synthesis platform.”

Church is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He also leads Synthetic Biology at the Wyss Institute. He developed the first direct genomic sequencing method, and helped initiate the Human Genome Project in 1984, the Personal Genome Project in 2005, and GP-Write in 2016. He has also helped founded more than 14 biotech companies, such as Editas, Gen9bio, Veritas Genetics and eGenesis.

Nuclera receives £250k grant from Innovate UK

01 / 07 / 2015

Nuclera has been awarded a Development of Prototype Smart Grant worth £250k from Innovate UK, the UK governments innovation agency. Building on advances made during an initial Proof of Concept Smart Grant, this second award will accelerate development of a fully functional prototype of Nuclera's next-generation DNA synthesis platform. We are grateful for the continued support from Innovate UK.

Innovate UK is the new name for the Technology Strategy Board – the UK’s innovation agency. Taking a new idea to market is a challenge. Innovate UK funds, supports and connects innovative businesses through a unique mix of people and programmes to accelerate sustainable economic growth. For further information visit www.innovateuk.org

Managed by Innovate UK, the Smart scheme offers funding to small and medium-sized enterprises (SMEs) to engage in R&D projects in the strategically important areas of science, engineering and technology, from which successful new products, processes and services could emerge. 

Nuclera receives £25k grant from Nwes 'Ready, Set, Go' initiative

01 / 07 / 2014

An NWES panel has awarded Nuclera a £25k grant for development of their next-generation synthesis platform and associated intellectual property costs incurred. In addition to this funding, NWES will be providing Nuclera with business development advice across areas including marketing, finance and legal operations.

The NWES enterprise agency specialises in helping people turn business ideas into reality by offering professional advice and access to business training courses. The 'Ready, Set, Go' programme is part funded by the European Regional Development Fund. It was launched in 2013 to provide free, independent and impartial business advice to pre-starts and established businesses looking to develop or introduce new products, processes and ideas.

Nuclera receives £100k grant from Innovate UK

01 / 05 / 2014

A successful Proof of Concept Smart Grant application has led to Nuclera obtaining £100k of non-dilutive funding from Innovate UK, the UK governments innovation agency. The grant will support research and development activities to advance key components of Nuclera's novel DNA synthesis process.

Innovate UK is the new name for the Technology Strategy Board – the UK’s innovation agency. Taking a new idea to market is a challenge. Innovate UK funds, supports and connects innovative businesses through a unique mix of people and programmes to accelerate sustainable economic growth. For further information visit www.innovateuk.org

Managed by Innovate UK, the Smart scheme offers funding to small and medium-sized enterprises (SMEs) to engage in R&D projects in the strategically important areas of science, engineering and technology, from which successful new products, processes and services could emerge. 

Nuclera receives £500k seed-funding investment

01 / 05 / 2014

Nuclera Nucleics Ltd. received an initial investment of £500k ($822k) for the development of a next-generation synthesis platform. 

Nuclera Nucleics is a next-generation DNA synthesis company, changing the paradigm of long DNA synthesis by enabling efficient synthesis of long strands of DNA in short timeframes. The Nuclera platform will make long DNA strands a readily available tool, and thus help expand research horizons and accelerate R&D of nucleic acid based pharmaceuticals.